AI Insight
A new study from Karolinska Institutet challenges the current binary classification of breast cancer as either estrogen receptor-positive or negative. Researchers found that this simplified categorization may miss crucial biological variations among patients that could influence optimal treatment strategies. The findings suggest a need for more nuanced classification systems to better capture the heterogeneity of breast cancer.
Why it matters
This research could lead to more personalized treatment approaches for breast cancer patients by recognizing that hormone-sensitive cancers are not all alike. Refining classification systems may help clinicians select more targeted therapies and improve patient outcomes by matching treatments to specific tumor characteristics.
Understand the Science
Breast cancer is often classified as either estrogen receptor-positive (hormone-sensitive) or not. However, a new study from Karolinska Institutet suggests that this simplified classification may overlook important biological differences between patients that could affect treatment decisions. The results are published in The Lancet Regional Health – Europe.
Source: Standard breast cancer classification may overlook important differences